Nurix Therapeutics' stock plummeted 5% during intraday trading on Friday, reflecting heightened investor concerns following recent financial disclosures and risk assessments.

The decline comes after the company reported its fourth-quarter fiscal 2025 results, revealing a basic EPS loss of $0.82 on revenue of $13.6 million. Analysis highlighted ongoing profitability challenges, with trailing twelve-month losses reaching $264.46 million against revenue of $84.0 million, and expectations that the company won't achieve profitability within the next three years. Additionally, the stock trades at a rich 21.5x P/S multiple compared to industry peers, and shareholders have experienced material dilution over the past year.

Further pressure emerged from a separate disclosure indicating significant foreign exchange risk due to unhedged currency exposure, adding another layer of uncertainty for investors already concerned about the company's financial trajectory.